Journal Article

Latest additions:
2024-04-19
15:49
[DKFZ-2024-00830] Journal Article
; ; ; et al
Phosphatidylinositol 4-kinase III alpha governs cytoskeletal organization for invasiveness of liver cancer cells.
High expression of phosphatidylinositol 4-kinase III alpha (PI4KIIIα) correlates with poor survival rates in patients with hepatocellular carcinoma (HCC). In addition, Hepatitis C virus (HCV) infections activate PI4KIIIα and contribute to HCC progression. [...]

Detailed record - Similar records
2024-04-19
15:44
[DKFZ-2024-00829] Journal Article
; ; ; et al
Reserpine-induced rat model for depression: Behavioral, physiological and PET-based dopamine receptor availability validation.
Reserpine (RES), a Vesicular Monoamine Transporter 2 (VMAT2) inhibitor agent, has been used in preclinical research for many years to create animal models for depression and to test experimental antidepressant strategies. Nevertheless, evidence of the potential use and validity of RES as a chronic pharmacological model for depression is lacking, and there are no comprehensive studies of the behavioral effects in conjunction with molecular outcomes.Experiment 1. [...]

Detailed record - Similar records
2024-04-19
15:39
[DKFZ-2024-00828] Journal Article (Review Article)
; ;
Murine Alox8 versus the human ALOX15B ortholog: differences and similarities.
Human arachidonate 15-lipoxygenase type B is a lipoxygenase that catalyzes the peroxidation of arachidonic acid at carbon-15. The corresponding murine ortholog however has 8-lipoxygenase activity. [...]

Detailed record - Similar records
2024-04-19
15:37
DBCoverage [DKFZ-2024-00827] Journal Article
; ; ; et al
Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.
Acute myeloid leukemia (AML) remains a therapeutic challenge despite recent therapeutic advances. Although monoclonal antibodies (mAbs) engaging natural killer (NK) cells via antibody-dependent cellular cytotoxicity (ADCC) hold promise in cancer therapy, almost none have received clinical approval for AML, so far. [...]

Detailed record - Similar records
2024-04-19
15:35
[DKFZ-2024-00826] Journal Article
; ; ; et al
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Clonal hematopoiesis (CH) driven by mutations in the DNA damage response (DDR) pathway is frequent in patients with cancer and is associated with a higher risk of therapy-related myeloid neoplasms (t-MNs). Here, we analyzed 423 serial whole blood and plasma samples from 103 patients with relapsed high-grade ovarian cancer receiving carboplatin, poly(ADP-ribose) polymerase inhibitor (PARPi) and heat shock protein 90 inhibitor (HSP90i) treatment within the phase II EUDARIO trial using error-corrected sequencing of 72 genes. [...]

Detailed record - Similar records
2024-04-19
15:32
[DKFZ-2024-00825] Journal Article (Review Article)
; ; ; et al
Luciferase- and HaloTag-based reporter assays to measure small-molecule-induced degradation pathway in living cells.
The rational development of small-molecule degraders (e.g., proteolysis targeting chimeras) remains a challenge as the rate-limiting steps that determine degrader efficiency are largely unknown. Standard methods in the field of targeted protein degradation mostly rely on classical, low-throughput endpoint assays such as western blots or quantitative proteomics. [...]

Detailed record - Similar records
2024-04-18
14:26
[DKFZ-2024-00824] Journal Article
; ; ; et al
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.
In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as intracellular costimulatory domain are in routine clinical use. [...]

Detailed record - Similar records
2024-04-18
14:22

Detailed record - Similar records
2024-04-18
14:20
[DKFZ-2024-00822] Journal Article
; ; ; et al
Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.
Patients with pediatric low-grade gliomas (pLGGs), the most common primary brain tumors in children, can often benefit from MAPK inhibitor (MAPKi) treatment. However, rapid tumor regrowth, also referred to as rebound growth, may occur once treatment is stopped, constituting a significant clinical challenge.Four patient-derived pediatric glioma models were investigated to model rebound growth in vitro based on viable cell counts in response to MAPKi treatment and withdrawal. [...]

Detailed record - Similar records
2024-04-18
14:10
[DKFZ-2024-00821] Journal Article
; ; ; et al
Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.
Brain nn, nn () [10.1093/brain/awae110]  GO
Epstein-Barr virus (EBV) infection has been advocated as a prerequisite for developing multiple sclerosis (MS) and possibly the propagation of the disease. However, the precise mechanisms for such influences are still unclear. [...]

Detailed record - Similar records